Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I)

Thrombosis and Haemostasis

Volumn 88, Issue 2, 2002, Pages 253-258

  De Bosch, N B ^a   Mosesson, M W ^a   Ruiz Saez A ^a   Echenagucia, M ^a   Rodriguez Lemoin, A ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Afibrinogenemia; Antithrombin; Fibrinogen; Hemostasis; Thrombin

Indexed keywords

ANTITHROMBIN; BATROXOBIN; FIBRIN; FIBRINOGEN; FIBRINOGEN 2; HIRUGEN; THROMBIN; UNCLASSIFIED DRUG;

ADSORPTION; AFIBRINOGENEMIA; ARTERY THROMBOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DYSFIBRINOGENEMIA; FIBRINOGEN BLOOD LEVEL; HUMAN; METABOLIC ACTIVATION; PLASMA; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0036339014     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613195     Document Type: Article

References (41)

1. Effects of γ'/γA chain fibrin on the plasma thrombin generation in afibrinogenemia
2. Fibrinogen and fibrin polymerization: An appraisal of the binding events that accompany fibrin generation and fibrin clot assembly
3. Identification and characterization of the thrombin binding sites on fibrin
4. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ')
5. Subfractions of human fibrinogen: Preparation and analysis
6. Human fibrinogen heterogeneities. III. Identification of γ chain variants
7. Human plasma fibrinogen heterogeneity: Evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (γ')
8. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin
9. Nécrose ischémique bilatérale dans un cas de grande hypofibrinogénémie congénitale
10. Thrombose massive des vaisseaux d'un membre au cours d'une hypofibrinémie congénitale
11. Hyfibrinogenemia and massive thrombosis
12. Fatal pulmonary embolism in congenital fibrinopenia
13. Congenital afibrinogenemia: Vascular changes and multiple thrombosis induced by fibrinogen infusions and contraceptive medication
14. Multiple pulmonary emboli in a patient with afibrinogenaemia
15. Thrombose portale révélatrice d'une afibrinogénémie congénitale
16. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers
17. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen
18. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin
19. Coagulation profile in afibrinogenemia
20. Plasma factor XIII binds specifically to fibrinogen molecules containing γ' chains
21. Polymerization site in the β chain of fibrin: Mapping of the Bβ1-55 sequence
22. The amino acid sequences in fibrin responsible for high affinity thrombin binding
23. 2-terminus
24. The polymerization and thrombin-binding properties of des-(Bβ 1-42)-fibrin
25. Fibrinogen Naples I (Bβ A68T) non-substrate thrombin binding capacities
26. Fibrinogen γ′ chain binds thrombin exosite II
27. A player of many parts: The spotlight falls on thrombin's structure
28. Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition
29. Note on the adsorption of thrombin on fibrin
30. Multiple protein interactions as exhibited by the blood-clotting mechanism
31. Fibrin, a factor influencing the consumption of prothrombin in coagulation
32. Congenital afibrinogenemia. A study of some basic aspects of coagulation
33. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution
34. The binding of thrombin by fibrin
35. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity
36. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
37. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity
38. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
39. Human thrombi contain an abundance of active thrombin
40. Defective thrombin binding by abnormal fibrin associated with recurrent thrombosis
41. Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia